Navigation Links
Sinovac Reports Third Quarter 2008 Unaudited Financial Results
Date:11/18/2008

would be retroactive to January 1, 2008, according to the newly enacted Enterprises Income Tax Law. Assuming HNTE is received, the impact on the results of operations for the nine months ended September 30, 2008 would include a $1,667,726 decrease in the provision of the current income tax with a corresponding reduction in the income tax liability and a $905,687 increase in deferred income tax expense with an offset to deferred income tax assets. The change of rate will be recorded in the period that changes occur.

As of September 30, 2008, Sinovac's cash and cash equivalents totaled $20.5 million, compared to $18.8 million as of June 30, 2008. The 9% increase in cash and cash equivalents compared to the second quarter of 2008 was primarily attributable to improved accounts receivables collection.

Nine Months Ended September 30, 2008

For the nine months ended September 30, 2008, sales reached $34.1 million, compared to $24.3 million for the same period of 2007, representing a 40% growth rate.

During the nine months ended September 30, 2008, Sinovac sold 5.3 million doses of Healive(R), compared to 4.1 million doses for the same period of 2007. The Company sold 234,000 doses of Bilive(R) during the 2008 period, compared to nil doses in the prior year period. As mentioned previously, the year- over-year change in sales was in line with the Company's sales and marketing strategy. For the first nine months of 2008, Healive, Anflu, and Bilive as a percentage of sales represented 91%, 5% and 4%, respectively.

Gross profit for nine months ended September 30, 2008 was $28.8 million, with a gross margin of 84.4%, compared to $20.7 million and 85.2% for the same period of 2007. The change in gross margin as a percentage of sales was primarily attributable to the product sales mix during the 2008 period.

Total operating expenses for the nine months ended September 30,
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sinovac Named to Deloitte Technology Fast 50 China
2. Sinovac to Participate in Two Upcoming Investor Conferences
3. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
4. Sinovac Biotech Holds 2007 Annual General Meeting
5. Sinovac to Present at the 2008 UBS Global Life Sciences Conference
6. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
7. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
8. Sinovac Adjourns Annual General Meeting
9. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
10. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
11. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... North American crystal oscillator market report defines and segments ... of revenue. This market was valued at $531.4 million ... by 2018, at a CAGR of 3.3% from 2013 ... North American crystal oscillator market report, to get an ... a glimpse of the segmentation of the market, and ...
(Date:10/22/2014)... Currently offering a comprehensive portfolio ... Weighing, Rice Lake, and Ohaus, Pipette.com has added ... Sartorius CPA Semi-Micro Balance is ideal for lab ... user-friendly laboratory balance. , Sartorius is a global ... balances are well known for their high performance, ...
(Date:10/22/2014)... ROCKVILLE, Md. , Oct. 22, 2014   ... company developing novel pathogen-specific therapies for serious infections and ... Office has issued a Notice of Allowance for a ... product in its C. difficile program, SYN-004. This ... to SYN-004 in the U.S. and adds to the ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... DIEGO, Jan . 8 Arena Pharmaceuticals, Inc. (Nasdaq: ... to present at the 27th Annual J.P. Morgan Healthcare Conference ... p.m. Eastern Time) at the Westin St. Francis Hotel in ... is scheduled to provide an overview of the company, including ...
... 8 Palomar Medical Technologies, Inc. (Nasdaq: ... of light-based systems for cosmetic treatments, today announced ... the Swedish company Q-MED AB (OMX Nordic Exchange, ... based in Uppsala, Sweden. The international distribution ...
... SAN DIEGO, Jan. 7 Volcano Corporation,(Nasdaq: ... sales of,products for the diagnosis and treatment of coronary ... its previously announced acquisition of,Axsun Technologies, Inc. , ... manufacturer of lasers and optical,engines used in medical Optical ...
Cached Biology Technology:Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference 2Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference 3Palomar and Q-MED AB Terminate International Distribution Agreement 2Palomar and Q-MED AB Terminate International Distribution Agreement 3Palomar and Q-MED AB Terminate International Distribution Agreement 4Palomar and Q-MED AB Terminate International Distribution Agreement 5Volcano Announces Closing of Axsun Technologies Acquisition 2
(Date:10/22/2014)... Inc. (NASDAQ: AWRE ), a leading supplier of ... third quarter ended September 30, 2014. Revenue for ... of 40% compared to $4.3 million in the same quarter ... was $4.1 million compared to $1.0 million in the third ... month period was primarily due to: i) a $1.0 million ...
(Date:10/18/2014)... genetic conditions, a certain type of exome sequencing method ... traditional molecular diagnostic methods, according to a study appearing ... to coincide with the American Society of Human Genetics ... region of the genome (the complete set of genes ... has been rapidly applied in research settings and recent ...
(Date:10/17/2014)... available in German . ... few drugs. When treating overdoses, doctors are often limited to ... if there is a combination of drugs involved. So what ... swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux from the ... an answer to this question. "The task was to develop ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Emergency aid for overdoses 2Emergency aid for overdoses 3
... better understanding of brain injury, a way to rejuvenate ... monitor their glaucoma at home, number among this years ... What surprises me every time I walk through ... involving so many NJIT graduate and undergraduate students, said ...
... French . , A new brain-imaging study by ... ghrelin - a stomach hormone, acts on specific regions of ... and eating for pleasure. This study, published in the ... understanding and treating obesity, a condition affecting millions world-wide. ...
... The potential of no-tillage (NT) soils for increasing the soil ... Most of the previous studies about SOC accrual in NT ... depth), and not for the whole soil profile. The lack ... to conclusively ascertain the effects of NT farming on SOC ...
Cached Biology News:NJIT applauds students for studies on brain injury, glaucoma and more 2Hunger hormone: Makes food more attractive 2Finding the real potential of no-till farming for sequestering carbon 2
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 beta, CF...
SHEEP ANTI FLECAINIDE...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: